이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Jiangsu Kanion PharmaceuticalLtd 관리

관리 기준 확인 3/4

Jiangsu Kanion PharmaceuticalLtd's CEO는 Yongchun Yang, Apr2021 에 임명되었습니다 의 임기는 3.17 년입니다. 는 CN¥ 3.45M 가치에 해당하는 회사 주식의 0.036% 직접 소유합니다. 3.45M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 2.6 년입니다.

주요 정보

Yongchun Yang

최고 경영자

CN¥758.6k

총 보상

CEO 급여 비율	n/a
CEO 임기	3.5yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	2.2yrs
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

CEO

Yongchun Yang (51 yo)

3.5yrs

테뉴어

CN¥758,600

보상

Mr. Yongchun Yang is General Manager at Jiangsu Kanion Pharmaceutical Co. Ltd. since April 9, 2021 and has been its Director since December 27, 2019. Mr. Yang served as Chief Marketing Officer and Deputy G...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yongchun Yang	GM & Director	3.5yrs	CN¥758.60k	0.036% CN¥ 2.9m
Suocheng Jiang	Deputy Chief Accountant	1.8yrs	CN¥207.50k	0.0043% CN¥ 349.6k
Feipeng Xian	Deputy General Manager	1.3yrs	CN¥521.10k	0.0069% CN¥ 559.0k
Haixin Gao	Board Secretary & Director	less than a year	CN¥1.05m	0.024% CN¥ 2.0m
Quan Liu	Deputy General Manager	4.8yrs	CN¥742.70k	0.024% CN¥ 2.0m
Yu Pan	Deputy GM & Market Development Center	2.6yrs	CN¥1.07m	0.024% CN¥ 2.0m
Yun Wu	Deputy General Manager	1.3yrs	CN¥637.00k	0.018% CN¥ 1.5m
Chuanlei Wang	Deputy General Manager	2.6yrs	CN¥710.40k	0.024% CN¥ 2.0m

2.2yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: 600557 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yongchun Yang	GM & Director	4.8yrs	CN¥758.60k	0.036% CN¥ 2.9m
Haixin Gao	Board Secretary & Director	1.3yrs	CN¥1.05m	0.024% CN¥ 2.0m
Wei Xiao	Chairman	23.9yrs	CN¥2.39m	2.95% CN¥ 237.7m
Zhenzhong Wang	Vice Chairman of the Board	8.1yrs	CN¥1.03m	0.036% CN¥ 2.9m
Meiling Jiang	Supervisor	1.3yrs	데이터 없음	데이터 없음
Min Xu	Independent Director	3.4yrs	CN¥100.00k	데이터 없음
Kaixian Chen	Independent Director	4.8yrs	CN¥100.00k	데이터 없음
Wu Di	Supervisor	2.4yrs	데이터 없음	데이터 없음
Xuebin Chen	Director	1.3yrs	CN¥641.10k	0.0097% CN¥ 782.9k
Lin Jiang	Supervisor	1.3yrs	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

47.5yo

평균 연령

경험이 풍부한 이사회: 600557 의 이사회는 경험(평균 재직 기간 2.6 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Jiangsu Kanion PharmaceuticalLtd 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 2Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Jul 27, 2024

First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.25 in 1Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 13, 2024

Investor sentiment improves as stock rises 18%

Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024

Full year 2023 earnings released: EPS: CN¥0.93 (vs CN¥0.75 in FY 2022)

Now 20% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) announces an Equity Buyback for CNY 150 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Now 23% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 11, 2024

New minor risk - Share price stability

Now 20% undervalued

Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 2Q 2022)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Jul 13, 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 1Q 2022)

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.75 (vs CN¥0.56 in FY 2021)

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.081 in 3Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.14 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.081 (vs CN¥0.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.10 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.86 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: CN¥9.43

New 90-day low: CN¥10.99

New 90-day low: CN¥12.14

Third quarter earnings released

New 90-day low: CN¥12.29

New 90-day low - CN¥12.67

New 90-day low - CN¥12.93

First half earnings released

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령